With several members receiving termination letters and its webpage archived, public health experts believe the days are ...

The Advisory Committee on Immunization Practices voted Wednesday to recommend lowering the age at which adults can get a ...

Notes from a recent meeting of the CDC’s Advisory Committee on Immunization Practices’ COVID-19 Work Group show health ...

Members of the Advisory Committee on Immunization Practices voted to expand the options for meningococcal vaccines and to ...

On Wednesday, the Advisory Committee on Immunization Practices (ACIP) voted to expand its recommendation for the use of ...

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that during its regular meeting on April 16, the U.S. Centers for Disease Control and Prevention’s (CDC) ...

In the first meeting of the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP) ...

US Advisory Committee on Immunization Practices recommends approval of GSK’s RSV vaccines, Arexvy for adults aged 50-59: London, UK Saturday, April 19, 2025, 09:00 Hrs [IST] GSK ...

The updated recommendation lowers the recommended age for RSV vaccination from 60 to 50 years in adults who are at high risk. The US Centers for Disease Control and Prevention’s (CDC) Advisory ...

The ACIP voted that Penmenvy may be used as part of the adolescent meningococcal vaccination schedule as an alternative to separate administration of MenACWY and MenB. The Centers for Disease ...

Advisory Committee on Immunization Practices (ACIP) has voted to recommend use of PENMENVY (Meningococcal Groups A, B, C, W, and Y Vaccine) as part of the adolescent meningococcal vaccination ...

Tony Wood, Chief Scientific Officer, GSK: “We are pleased with ACIP's recommendation to expand the benefits of RSV immunization to more than 13 million adults aged 50-59 who are at increased ...